Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


DDAVP 0.1mg Tablets 1X100 Each By Sanofi - Aventis Us Llc

Image 0 of DDAVP 0.1mg Tablets 1X100 Each By Sanofi - Aventis Us LlcImage 1 of DDAVP 0.1mg Tablets 1X100 Each By Sanofi - Aventis Us LlcImage 2 of DDAVP 0.1mg Tablets 1X100 Each By Sanofi - Aventis Us Llc

DDAVP 0.1mg Tablets 1X100 Each By Sanofi - Aventis Us Llc

Call for Price

DDAVP 0.2mg Tablets 1X100 each Mfg.by: Sanofi - Aventis Us Llc USA. This item requires a valid order from a physician licensed in the USA. Item No.:RXD2416824 NDC No.: 00075-0026-00 Category: Desmopressin Acetate Compare to:
UPC No.: 300750016000 Mfg.Item No.:1600

Have a question?

  Call for Price

DESCRIPTION:0.1, 36 AV
tablet , white , scored , oval oblong

DDAVP? Tablets (desmopressin acetate) are a synthetic analogue of the natural pituitary hormone 8-arginine vasopressin (ADH), an antidiuretic hormone affecting renal water conservation.

DDAVP Tablets contain either 0.1 or 0.2 mg desmopressin acetate. Inactive ingredients include: lactose, potato starch, magnesium stearate and povidone.

INDICATIONS

Central Diabetes Insipidus: DDAVP Tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. DDAVP is ineffective for the treatment of nephrogenic diabetes insipidus.

Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to DDAVP can be monitored by measuring urine volume and osmolality.

Primary Nocturnal Enuresis: DDAVP Tablets are indicated for the management of primary nocturnal enuresis. DDAVP may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention.

SIDE EFFECTS

Infrequently, large doses of the intranasal formulations of DDAVP and DDAVP Injection have produced transient headache, nausea, flushing and mild abdominal cramps. These symptoms have disappeared with reduction in dosage.

Central Diabetes Insipidus: In long-term clinical studies in which patients with diabetes insipidus were followed for periods up to 44 months of DDAVP Tablet therapy, transient increases in AST (SGOT) no higher than 1.5 times the upper limit of normal were occasionally observed. Elevated AST (SGOT) returned to the normal range despite continued use of DDAVP Tablets.

Primary Nocturnal Enuresis: The only adverse event occurring in ≥ 3% of patients in controlled clinical trials with DDAVP Tablets that was probably, possibly, or remotely related to study drug was headache (4% DDAVP, 3% placebo).

Other: The following adverse events have been reported however their relationship to DDAVP has not been established: abnormal thinking, diarrhea, and edema-weight gain.

See WARNINGS for the possibility of water intoxication and hyponatremia.

Post Marketing: There have been rare reports of hyponatremic convulsions associated with concomitant use with the following medications: oxybutinin and imipramine.